Overview of Dr. Shah
Dr. Manish Shah is an oncologist in New York, NY and is affiliated with NewYork-Presbyterian/Weill Cornell, and New York-Presbyterian Hospital. He received his medical degree from Harvard Medical School and has been in practice 21 years. He specializes in gastrointestinal oncology and drug development. Dr. Shah is Chief of the Solid Tumor Service and co-Director for the Center for Advanced Digestive Care at New York-Presbyterian.
Office
1305 York Ave
New York, NY 10021Fax+1 646-962-1606
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1999 - 2001
- Duke University HospitalResidency, Internal Medicine, 1996 - 1999
- Harvard Medical SchoolClass of 1996
- Johns Hopkins UniversityB.E.S., 1987 - 1991
Certifications & Licensure
- NJ State Medical License 2022 - 2025
- NY State Medical License 1999 - 2024
- NC State Medical License 1997 - 2000
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Department of Medicine Young Investigators Award 2014
- Donald L. Morton Award Journal for Surgical Oncology, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
- Join now to see all
Clinical Trials
- BMS-247550 in Treating Patients With Metastatic Stomach Cancer Previously Treated With Chemotherapy Start of enrollment: 2001 Feb 01
- BMS-247550 in Treating Patients With Recurrent Metastatic Stomach Cancer That Has Been Previously Treated With Chemotherapy Start of enrollment: 2001 Feb 01
- Combination Chemotherapy in Treating Patients With Advanced Solid Tumors Start of enrollment: 2002 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 6 citationsSociety for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer.Ronan J Kelly, Katherine Bever, Joseph Chao, Kristen K Ciombor, Cathy Eng
Journal for Immunotherapy of Cancer. 2023-06-01 - 562 citationsPembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phas...Jong-Mu Sun, Lin Shen, Manish A. Shah, Peter C. Enzinger, Antoine Adenis
Lancet. 2021-08-28 - 339 citationsEfficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 ...Manish A. Shah, Takashi Kojima, Daniel Hochhauser, Peter C. Enzinger, Judith Raimbourg
JAMA Oncology. 2019-04-01
Journal Articles
- Template for Reporting Results of HER2 (ERBB2) Biomarker Testing of Specimens From Patients With Adenocarcinoma of the Stomach or Esophagogastric JunctionBartley AN, Christ J, Fitzgibbons PL, et al, Archives of pathology & laboratory medicine, 10/2/2014
- The role of (1)(8)F-FDG PET imaging in upper gastrointestinal malignanciesDai T, Popa E, Shah MA, Current treatment options in oncology, 9/1/2014
- Is gastric cancer different in Korea and the United States? Impact of tumor location on prognosisShim JH, Song KY, Jeon HM, Park CH, Jacks LM, Gonen M, Shah MA, Brennan MF, Coit DG, Strong VE, Ann Surg Oncol, 7/1/2014
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Cancers of the Esophagus and Stomach.Shah MA, Gastrointestinal Cancers Symposium, San Francisco, CA, 1/16/2014
- Survival analysis according to disease subtype in AVAGAST: First-line capecitabine and cisplatin plus bevacizumab (bev) or placebo in patients with advanced gastric ca...Shah MA, Gastrointestinal Cancers Symposium, San Francisco, CA, 1/19/2012
- Phase II study of preoperative chemotherapy with irinotecan and cisplatin for gastric cancer (NCI 5917): FDG PET/CT predicts patient outcome.Shah MA, ASCO, 6/3/2007
Lectures
- Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study.2019 ASCO Annual Meeting - 6/1/2019
- Pembrolizumab for patients with previously treated metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: Phase 2 KEYNOTE-180 study.2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
- Targeted therapies in gastric cancer.Madrid, Spain - 6/26/2014
- Join now to see all
Press Mentions
- Zolbetuximab Improves Survival in Gastric CancerMarch 26th, 2023
- Astellas Announces Positive Findings from Phase 3 GLOW Trial of … – PR NewswireMarch 21st, 2023
- Major Immune Cells Maintain Healthy Gut Bacteria to Protect Against Colorectal CancerAugust 31st, 2021
- Join now to see all
Professional Memberships
- Member
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Illinois PPO
BCBS Minnesota Blue Cross Accord
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Choice
First Health PPO
GHI PPO
Great West PPO
Health Alliance PPO
Health Net Oregon PPOHealthfirst New York
HIP of New York - Select PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
ODS Network
Oxford Health Freedom
Oxford Health Liberty
Premera BCBS Heritage & Heritage Plus 1
Providence Health System Personal Option
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Wellmark Alliance Select - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: